Paclitaxel also binds to Toll-like receptor 4 (TLR-4), activating TLR-4 downstream signaling pathways that lead to the synthesis of many proinflammatory mediators during inflammation, some of which are crucial in carcinogenesis and tumor growth. Here, TLR4 is linked to neoplasm.